Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07831330 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer

Name: Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer — clinical trial record (NCT07831330)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2026-09-05

View on ClinicalTrials.gov ↗

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This is a prospective, multicenter, open-label, single-arm study in participants with metastatic pancreatic adenocarcinoma who have not received any prior systemic anti-tumor therapy for advanced disease. To evaluate the efficacy and safety of albumin-bound paclitaxel (II) combined with gemcitabine for first-line treatment of metastatic pancreatic cancer.

Trial Details

NCT Number	NCT07831330
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Metastatic Pancreatic Adenocarcinoma, Albumin-bound Paclitaxel (II), Gemcitabine, First-Line
Enrollment	59 participants
Start Date	2026-09-05
Primary Completion	2029-01-31 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-21